The Journal for ImmunoTherapy of Cancer
is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.
Impact Factor: 10.3
Citescore: 17.7
All metrics >>
Highlighted Articles
Authors
The Journal for ImmunoTherapy of Cancer accepts a variety of article types in a number of formats.
The Author Information section provides specific article requirements and section outlines to help you turn your research into an article suitable for JITC.
Information is also provided on editorial policy, Open Access fees and formatting.
Latest Articles
Immune cell therapies and immune cell engineering:
Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma28 March 2025
Position article and guidelines:
SITC strategic vision: prevention, premalignant immunity, host and environmental factors28 March 2025
Letter:
Comment on ‘Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types’28 March 2025
Clinical cancer immunotherapy:
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events28 March 2025
Most Read Articles
Position article and guidelines:
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision19 June 2024
Clinical/translational cancer immunotherapy:
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer23 October 2024
Immune cell therapies and immune cell engineering:
Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering18 October 2023
Position article and guidelines:
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy29 February 2024
Altmetrics
Become a Reviewer for JITC
JITC offers many benefits to those who review for the journal, including discounts on Article Processing Charges (APC). Learn more about becoming a reviewer for JITC and volunteer for the role.
The journal also offers a Peer Review Mentorship Program for early career professionals with limited peer reviewing experience. A limited number of successful applicants are paired with senior leaders who help provide structural guidance on peer review to young researchers. Check the link below in summer for more information on key dates and how to apply to be a mentee in the next class.
About SITC
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC provides members with a 25% discount on Article Processing Charges (APCs) on papers where they serve as first, last, or corresponding author. This discount is applied post-acceptance, at which point a discount code is shared with the corresponding author.
For information on APC discounts and waivers – including those for members, editors or reviewers, low-income countries, or institutional arrangements – view the journal's APC policy.